<- Go Home

PharmaSGP Holding SE

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It also exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.

Market Cap

EUR 330.9M

Volume

606.00

Cash and Equivalents

EUR 37.8M

EBITDA

EUR 35.5M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 103.7M

Profit Margin

90.94%

52 Week High

EUR 27.60

52 Week Low

EUR 19.00

Dividend

4.93%

Price / Book Value

8.91

Price / Earnings

17.61

Price / Tangible Book Value

-13.99

Enterprise Value

EUR 363.1M

Enterprise Value / EBITDA

10.09

Operating Income

EUR 26.8M

Return on Equity

51.14%

Return on Assets

12.85

Cash and Short Term Investments

EUR 37.8M

Debt

EUR 69.9M

Equity

EUR 36.9M

Revenue

EUR 114.0M

Unlevered FCF

EUR 23.4M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches